TD Cowen raised the firm’s price target on AstraZeneca (AZN) to $105 from $95 and keeps a Buy rating on the shares. The firm said the company has promising new products and pipeline and participates in many large, high-growth markets. Numerous events are upcoming for investors to assess progress. EPS growth appears to be above industry average, with upside possible.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AZN:
- AstraZeneca, Daiichi Sankyo dose first patient in DESTINY-Ovarian01 trial
- AstraZeneca price target raised to 16,000 GBp from 14,000 GBp at JPMorgan
- JPMorgan ups AstraZeneca target, adds to Analyst Focus List
- Trump Weekly: President approves U.S. manufacturing of ‘tiny cars’
- Salesforce (CRM) Wins AstraZeneca Deal, Becomes the Unified Global Platform